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Antiplatelet therapy has been documented to reduce risks of cardiovascular disease after acute myocardial infarction, coronary
arterybypassgraft,andinchronicatrialﬁbrillationpatients,amongstotherriskfactors.Conventionalmanagementofthrombosis-
based disorders includes the use of heparin, oral anticoagulants, and the preferred antiplatelet agent aspirin. Interestingly, aspirin
wasnotintendedtobeusedasanantiplateletagent;rather,afterbeingrepurposed,ithasbecomeoneofthemostwidelyprescribed
antithrombotic drugs. To this end, there have been several milestones in the development of antiplatelet agents in the last few
decades, such as adenosine diphosphate receptor inhibitors, phosphodiesterase inhibitors, and GPIIb/IIIa inhibitors. However,
given some of the limitations of these therapies, aspirin continues to play a major role in the management of thrombotic and
cardiovascular disorders and is expected to do so for years to come.
1. Role of PlateletsinPrimaryHemostasis
and Atherothrombosis
Since the mechanism of action of acetyl salicylic acid
(aspirin) is based on platelets function, a complete knowl-
edge of platelets physiology and pharmacology in hemostatic
process is fundamental. Platelets were recognized as a
distinct blood element in the late 19th century. Experiments
performed in vivo by Bizzozero in 1882 demonstrated that
platelets (and not white blood cells) were responsible for
the formation of white clots at the sites of vascular injury
in guinea pig micro vessels [1]. Mammalian platelets are
enucleated cells arising from cytoplasmic fragmentation of
megakaryocytes in the bone marrow and have a typical
diameter of 2 to 3μm. Platelets circulate in a discoid form,
and their average lifespan in humans is about 10 days [2].
Despite their lack of a nucleus, platelets contain a variety of
mediators that regulate many processes from ﬁghting micro-
bial infection and triggering inﬂammation to promoting
tumor angiogenesis and metastasis [3–6]. Nevertheless, the
main function of platelets is to be essential mediators of the
process of hemostasis and thrombosis. In fact, platelets do
not interact with vascular walls under normal conditions,
but when a blood vessel is damaged at its luminal side,
platelets promptly adhere to the damaged subendothelial
matrix, which contains several adhesive macromolecules like
collagen, von Willebrand factor (vWF), laminin, ﬁbronectin,
and thrombospondin, to limit hemorrhage and promote
tissue healing.
In order to act as a hemostatic plug, relevant constituents
for thrombosis are present both on the cell membrane and
in the cytoplasm of platelets. The platelet membrane, which
consists of a bilayer of phospholipids, contains membrane
glycoproteins that interact with various ligands within the
vessel wall or on other cells, through which the platelets
adhere to the injured subendothelium and within each other.
The plasma membrane of platelets is a highly specialized
structure that contains a network of invaginations into the
interior of the cell, connected to the exterior through small
pores [7, 8], known as the open canalicular system, giving to
the platelet a greater surface area than expected for such a
small cell. Platelets contain a second channel system, derived
from megakaryocyte smooth endoplasmic reticulum, known
as the dense tubular system (DTS), which stores calcium and
a variety of enzymes involved in platelet activation. Inter-
estingly, the DTS system is not associated with the plasma
membrane [9, 10]. Calcium is a critical factor for platelets
function. It is the responsible of the dramatic changes2 Thrombosis
in shape and ultrastructure that platelets undergo after
the activation process, when platelets membranes become
ruﬄed with cytoplasmic projections and the granules found
inside the platelets are centralized and discharged [11, 12].
Accumulation of platelets at the site of vascular injury
includes (1) an initiation phase involving platelet adhesion,
(2) an extension phase that includes activation, additional
recruitment, and aggregation, and (3) perpetuation phase
characterized by platelet stimulation of the clot [13]. The
initial phase of primary hemostasis is characterized by
platelets adhesion and involves interactions between the
glyproprotein (GP) Ib-IX-V receptor complex and the A1
domain of vWF in the exposed subendothelium [14, 15].
Ex vivo studies with human blood have demonstrate that
GPIb-vWF is the primary adhesive interaction, initiating
platelet adhesion at high shear rates (>1000s−1)[ 16], as
found in arterial microvessels or arterioles [17]. Analogous
studies in mice (an increasingly studied experimental model
of thrombosis) reveal comparable shear rate-dependence
of GPIb-vWF-mediated adhesion occurring at higher shear
rates [18]. This is because the initial adhesive interactions
between platelets and the extracellular matrix depends on
the local rheological conditions. Thus, at low shear rates
(<1000−1 suchinveinsandlargerarteries),plateletsadhesion
involves binding to collagen, ﬁbronectin, and laminin. On
the other hand, at higher shear rates (>1000−1, when
a signiﬁcant reduction in vascular cross-sectional area is
present, such in small arteries and microvasculature, but
also as may result from thrombus, atherosclerotic plaque,
vasoconstriction, etc.), the interaction between the platelet
surface receptor and GPIα- v W Fi n t e r a c t i o n si sc r i t i c a lt o
slow down the ﬂow of platelets, allowing the establishment
of additional bonds, leading to deﬁnitive arrest of platelets
and subsequent thrombus formation [19, 20].
2.PlateletAdhesion Molecules
As previously mentioned, platelets contain a number of
adhesion molecules, both on the plasma membrane and
within their granules, which are relevant for hemostasis and
thrombosis,aswellascell-cellandcell-subendothelialmatrix
interactions. The cellular localization and activation state
of these molecules vary according to the state of platelet
activation.
2.1.P-Selectin. (CD62P, ∼140kd)isthelargestoftheselectin
family of adhesion molecules. It is contained primarily
on platelet α-granules and in the Weibel-Palade bodies of
endothelial cells. Under resting, unstimulated conditions,
only little P-selectin is evident on the surface of platelets.
However, following the activation of platelets (or endothelial
cells), the membrane of the granule merges with the mem-
brane of the cell, resulting in rapid expression of P-selectin
on the cell surface [21, 22]. P-selectin surface expression is
commonly used as a marker of platelet activation [23].
2.2. Glycoprotein Ib/IX/V (GPIb/IX/V). This large glycopro-
tein receptor complex is the main platelet receptor for vWF
and is composed of four distinct molecules [24]. Binding of
vWF to GPIb initiates signal transduction events that lead
to the activation of the platelet integrin GPIIb/IIIa, which
becomes competent to bind vWF or ﬁbrinogen to mediate
platelet aggregation. Deﬁciency or dysfunction of the GPIb
complexresultsinableedingdisorderknownastheBernard-
Soulier syndrome [25].
While this receptor is present constitutively on the
platelet plasma membrane and vWF is normally present
in plasma, binding of the receptor with its ligand induces
alterations in blood ﬂow and the resultant shear stress,
with a subsequent conformational change in either or both
components. This interaction is assessed in vitro using the
antibiotic ristocetin instead of shear stress [26].
2.3. Glycoprotein IIb/IIIa (GP IIb/IIIa). Platelet GP IIb/IIIa
(also known as αIIbβ3) is a heterodimeric transmembrane
protein molecule composed of one α subunit (GP IIb) and
a β subunit (GP IIIa), which belongs to the integrin family.
This molecule is expressed constitutively on the plasma
membrane as an inactive form in resting platelets. Upon
plateletactivation,theGPIIb/IIIaundergoesconformational
changes, thereby gaining the ability to bind ligands [27].
Platelet GPIIb/IIIa can bind to ﬁbrinogen as well as other
ligands such as vWF, ﬁbronectin, and vitronectin [28]. This
molecule represents a major target for directed therapy in
patients with thrombotic disorders [29].
2.4. Collagen Receptors. The α2β1 integrin and glycoprotein
VI (GPVI, ∼65kd) are the primary collagen receptors, which
play a prominent role in hemostasis. These receptors bind
to speciﬁc sequences on collagen with diﬀerent aﬃnities.
Platelet adhesion promoted by integrin α2β1 induces acti-
vation of platelet GPIIb/IIIa through the phospholipase
C- (PLC-) dependent stimulation of the small GTPase
Rap1b [30]. Platelet GPVI is expressed constitutively on
the platelet plasma membrane and is also expressed on
α-granules [31]. Following platelet activation, the surface
expression of GPVI increases and intracellular expression
decreases, consistent with their release from α-granules and
incorporation into the plasma membrane. GPVI belongs
to the immunoglobulin superfamily that contains two C2
immunoglobulin-like domains and an arginine residue in
the transmembrane region that forms a salt bridge with the
aspartic acid residue of the Fc receptor γ-( F c R γ-) chain
[32]. Activation by collagen leads to phosphorylation of its
immunoreceptor tyrosine-based activation motif (ITAM),
leading to a sequence of events involving several adaptor
proteins and resulting in phosphorylation and activation of
PLCγ2[33,34].GPVImainlybindstocollagentypesthatcan
form large collagen ﬁbrils such as collagen type III. Absence
of GPVI in humans is associated with a predisposition to
bleeding [35].
3. Platelets Activation, Additional Recruitment,
andAggregation
Followingtheinitial adhesionofplateletstothesiteofinjury,
platelets are activated by a process that occurs in 3 phases:
(1) the interaction of agonists with their respective plateletThrombosis 3
receptors and receptor-mediated early platelet activation
signaling,(2)theintermediatecommonsignalingevents,and
(3) integrin activation. Platelet adhesion receptors are the
key initiators of platelet activation at sites of vascular injury,
where platelets become exposed to adhesive proteins in the
matrix or on endothelial cells. Platelets are then activated by
a number of agonists such as adenosine diphosphate (ADP)
and collagen that are present at the sites of vascular injury.
These agonists activate platelets by binding to the afore-
mentioned receptors on the platelet surface described above.
Occupancy of these receptors leads to a series of downstream
eventsthatultimatelyincreasestheintracytoplasmicconline-
breakcentrationofcalciumions,byreleasefromintracellular
stores, and by calcium inﬂux through the plasma membrane
[36]. Receptors coupled to G-proteins, such as those to
ADP, thromboxane A2 (TXA2), and thrombin, activate
phospholipase Cβ(PLCβ), whereas receptors acting via the
nonreceptortyrosinekinasepathwayssuchascollagenrecep-
tor GPVI preferentially activate phospholipase Cγ(PLCγ)
[36]. Activation of PLCβ or PLCγ results in the production
of two second messengers: diacylglycerol (DAG) and inositol
trisphosphate (IP3). DAG mediates calcium inﬂux, while IP3
liberates calcium from intracellular stores. Calcium inﬂux
may also be induced directly by certain agonists, such as ATP
binding to the ligand-gated ion channel receptor, P2X1 [37].
As already pointed out, increased platelet-free calcium
concentration results in a number of structural and func-
tional changes of the platelet. Morphologically, the platelet
changes dramatically from a disc to a spinysphere (a pro-
cess called shape change). The granules in the platelet are
centralized, and their contents are discharged into the lumen
of the open canalicular system, from which they are then
released to the exterior (i.e., the “release reaction”). The
increase in platelet calcium stimulates membrane phospho-
lipase A2 activity, which liberates arachidonic acid (AA)
from membrane phospholipids. This AA is converted to
an intermediate product prostaglandin H2 (PGH2) by the
enzyme cyclooxygenase 1 (COX-1). PGH2 is further meta-
bolized to TXA2 by thromboxane synthase [38]. TXA2 is
a potent activator of platelets. The long membrane pro-
jections brought about by shape-change reaction allow the
platelets to interact with one another to form aggregates.
Shape change is mediated by the platelet cytoskeleton, com-
posed by an organized network of microtubules and actin
ﬁlaments and a number of associated proteins, linked to a
variety of platelet signaling molecules [39]. Platelet shape
changeresultsinextensive reorganizationofthecytoskeleton
network, polymerization of actin, and myosin light chain
phosphorylation[39–42];theseresponsesvaryinatime-and
stimulus-dependent manner.
4.Ampliﬁcation ofActivatedPlatelets
SignalTransduction:Receptor-Mediated
EarlyPlatelet ActivationSignalingand
Intermediate Common Signaling Events
Following platelet binding to the injured vessel wall and
subsequent signaling to the platelet cytoplasm, a controlled
release reaction takes place. Platelet granules fuse with the
outer membrane and empty their content into the local en-
vironment, ﬁlling it with a multitude of bioactive molecules.
Their para- and autocrine nature causes preliminary signals
to quickly feedback into the process by increasing activation
of nearby platelets in both number and magnitude, thereby
evoking secondary secretion, resulting in a drastic ampliﬁca-
tion of the platelet activation process [43].
In platelets, three types of granules are distinguished: α
granules, dense granules (δ), and lysosomes (γ granules).
Alpha (α) granules are the largest (∼200–400nm) and most
prevalentandheterogeneousplateletgranules[44,45].These
granules are responsible for a variety of eﬀects like primary
hemostasis,coagulation,inﬂammation,angiogenesis,wound
healing, and others. The deﬁnitive proof of the importance
of α granules in hemostasis came from the evidence of the
consequences of its deﬁciency. Platelet α-granule deﬁciency
is a rare inherited disease, known as the gray platelet
syndrome (GPS). This illness is associated with quantitative
and qualitative platelet dysfunction and a bleeding predis-
position [46]. In GPS, proteins endogenously synthesized
by megakaryocytes or endocytosed by platelets fail to enter
α-granules of platelets due to abnormal formation of α-
granules during megakaryocytic diﬀerentiation. This results
in continued release of α-granule contents such as growth
factors and cytokines into the bone marrow resulting in
ﬁbrosis (myeloﬁbrosis) [46].
The α granules contain the majority of platelet factors
involved in hemostasis and thrombosis. These include large
polypeptides such as thrombospondin, P-selectin, platelet
factor 4, and β-thromboglobulins. α-granules also contain a
variety of adhesion molecules involved in platelet-vessel wall
interaction such as ﬁbronectin and vitronectin. The mem-
brane of α-granules contains several proteins that are also
expressed on the platelet cell membrane such as GPIb com-
plex, GPVI and GP IIb/IIIa [47]. Besides the release of pro-
teinsimportantinprimaryhemostasis,αgranulescontribute
to secondary hemostasis. In fact, coagulation factors also
reside in the α granules (Factors V, XI, and XIII, ﬁbrinogen,
vWF, and high molecular weight kininogens). Controlled
ﬁbrin formation stabilizes platelet aggregates in environ-
ments of high shear stress, and stabilization of ﬁbrin threads
is assured through the simultaneous release of ﬁbrinolysis
inhibitors like plasminogen activator inhibitor-1 [48].
4.1. Dense Granules Release and Ampliﬁcation of Platelet
Signaling. Platelet dense granules are the smallest granules
(∼150nm) and appear as dense bodies on electron mi-
croscopy due to their high calcium and phosphate content
[9]. In addition, they contain high concentrations of adenine
nucleotides and serotonin. The nucleotide ADP is more
abundant and more potent than serotonin. It interacts with
two biochemically related purinergic G-coupled receptors
thatevokedistinctreactionsthroughseparatesignalingpath-
ways. Binding of ADP to P2Y1 causes platelet shape change
and aggregation through Gq-mediated phospholipase C-β2
[49,50].Theshapechangereactionprecedesaggregationand
increases the external platelet surface area, helping contacts
with nearby cells and matrix molecules. The binding of ADP4 Thrombosis
to its second receptor (i.e., P2Y12) induces the coupling
to Gα1 and decreases cAMP [51]. The P2Y12 receptor also
stimulates surface expression of P-selectin and secretion of
TXA2 [52]. This latter, short-lived prostanoid is of major
importance for signal ampliﬁcation through binding with
the thromboxane/endoperoxide receptor (abbreviated as
TPR), which, in turn, activates Gq and G13, thereby closing
the loop [53]. TXA2 is produced de novo and binds receptors
TPRα and TPRβ; however, its eﬀects in platelets are mediated
primarily/solely through TPRα [54]. Both ADP and TXA2
are secreted from adherent platelets and contribute to the
recruitment of circulating platelets and promote alterations
in platelet shape and granule secretion, thus platelet activa-
tion is ampliﬁed and sustained during the extension phase.
The importance of dense granules to normal hemostasis
is highlighted by the bleeding disorder produced in patients
with deﬁciency of these granules. Platelet dense granule de-
ﬁciency has been identiﬁed in two rare human conditions
associated with predisposition to bleeding: Hermansky-
Pudlak syndrome (HPS) and Chediak-Higashi syndrome
[55].HPSisdeﬁnedbypigmentdilution(aﬀectingskin,hair,
and eyes), resulting in oculocutaneous albinism and platelet
storage pool deﬁciency due to deﬁciency of dense granules.
HPS is due to mutations in genes that mostly function in
membrane and protein traﬃcking. There are eight known
human HPS genes, each resulting in speciﬁc clinical variants
of HPS [56]. Mouse strains that are deﬁcient in orthologous
genes also have been characterized and have a bleeding
diathesis [57]. Chediak-Higashi syndrome is a rare autoso-
mal recessive disorder characterized by oculocutaneousal-
binism,lymphnodeenlargement,hepatosplenomegaly(liver
and spleen enlargement), and recurrent infections [55, 58].
Platelet aggregation studies are consistent with deﬁciency in
the storage pool of dense granule substances and suggest that
thisgranuledefecthasaninﬂuenceonthereleasemechanism
of other granule constituents[59].
Lysosomes represent the third category of platelet gran-
ules, with a size intermediate between α- and dense granules
(∼200–250nm);theycontainanintraluminalacidicpHwith
hydrolytic enzymes active towards a number of substrates
including constituents of the extracellular matrix [9, 60].
While the functional role of platelet lysosomes is less well
understood than that of α- and dense granules, lysosome
release has been postulated to contribute to regulation of
thrombus formation and remodeling of the extracellular
matrix [9]. Whereas dense body contents are easily secreted,
a granule secretion only occurs with powerful activating
agents such as thrombin or high doses of collagen. In
addition to the contents of the three types of granules,
and as stated previously, platelets also produce and secrete
pharmacologically active substances such as TXA2 and the
platelet-activating factor (PAF) during their activation and
aggregation, which establish a positive feedback system.
5.Mechanismsof PlateletActivation:
PlateletsReceptors
Platelets can be activated by a variety of physiological
and pharmacological agents. All these agonists are believed
to exert their eﬀect through the interaction with speciﬁc
receptorsontheplateletplasmamembrane.Alloftheagonist
receptors, which interact/couple with guanine nucleotide-
binding regulatory proteins (G-proteins) or G-proteins that
have been identiﬁed to date, consist of a single polypeptide
with an extracellular N-terminal domain which serves as
the activator-binding domain, a seven hydrophobic trans-
membranedomains,andanintracellularC-terminaldomain
which is in connection with cytoplasmic second messenger
generating enzymes. The primary eﬀects of these agonists
are often enhanced by secondary eﬀects attributable to the
synthesis of TxA2 from released AA and to the secretion of
ADP [61].
The best known platelet receptors are as follows.
(1) vWF is present in the subendothelium and in plate-
lets. Upon binding to subendothelial components,
especially type VI collagen, vWF undergoes a confor-
mation change which enablesit to bind to platelet GP
Ib. This is one of the major sialogly coproteins of the
platelet membrane consisting of two disulﬁde-linked
subunits. The interaction between vWF and GP Ib
results in platelet activation and in the generation
of an intraplatelet signal necessary to activate GP
IIb/IIIa [62], thereby leading to platelets spreading
andirreversibleplateletadhesion,whichcanresistthe
high shear forces in blood circulation.
(2) Thrombin Receptor: thrombin is a very powerful
platelet stimulus, causing shape change, aggregation,
and secretion from dense granules, α granules, and
lysosomes. Its receptor is a member of the G-protein
coupled seven transmembrane family. It is cleaved by
thrombin between arginine 41 and serine 42, which
results in its activation. After thrombin activation,
desensitization to further thrombin activation occurs
with internalization of the thrombin receptors in
endosomes, where three quarter of the receptors are
transferred to lysosomes and degraded [63].
(3) Collagen Receptor: GPVI is the major platelet collagen
receptortomediatecellularactivation,whichisapre-
requisite for eﬃcient adhesion, aggregation, degran-
ulation, and coagulant activity on the matrix protein
[64–66]. GPVI (62kDa) is a type I transmembrane
receptor expressed exclusively in platelets and
megakaryocytes[67].GPVIhasonlyalowaﬃnityfor
collagen, which makes it similar to GPIbα,u n a b l et o
mediate adhesion by itself. It is now widely accepted
that although GPVI serves as a receptor, that is, es-
sential for platelet activation and aggregation by col-
lagen,italsocontributestoﬁrmadhesion.Thus,both
collagenreceptorsactsynergistically,reinforcingeach
other’s activity ensuring optimal platelet adhesion
and activation by collagen [68].
(4) ADPReceptors:therearetwoknownsubtypesofADP
receptors on human platelets P2Y1 which couples
with Gαq and contributes to initial aggregation,
and P2Y12 receptors which are coupled to Gα1
and decreased cAMP. P2Y12 also induces surfaceThrombosis 5
expression of P-Selectin and TxA2 [51]. A new
receptor has been characterized in mice and called
P(2T). In those animals, sustained ADP-induced
aggregation requires coactivation of P2Y1 and P(2T)
receptors. Studies using AR-C69931MX, a selective
P(2T) receptor antagonist and novel antithrombotic
agent, were performed lately to further characterize
this receptor. These studies have conﬁrmed that the
P(2T) receptor plays a central role in amplifying
platelet responses [69].
5.1. Platelet Role in Clot Formation. Activated platelets also
provide an eﬃcient catalytic surface for the assembly of the
enzyme complexes of the blood coagulation system [70–
72], known as secondary hemostasis. The classic descrip-
tion of coagulation involves a cascade model consisting
of two distinct pathways: the extrinsic, or tissue factor
pathway and the intrinsic pathway. These are now viewed
in terms of overlapping phases of initiation, ampliﬁcation,
and propagation. The coagulation system consists of a
number of serine proteases, cofactors, calcium, and cell
membrane components, and their reactions represent highly
complex interactions, subject to regulation at a number of
levels that eventually will lead to the formation of cross-
linked and insoluble interconnecting networks of strands.
This particular characteristic of platelets makes them an
important target for drug discovery and applications in the
ﬁeld of thrombosis pathologies.
The characteristics of the procoagulant activity on the
plateletsurfaceresemblethoseofsyntheticphospholipidsur-
faces. To be active in coagulation, the phospholipid surface
requires a net negative charge (provided by phosphatidylser-
ine, phosphatidylinositol, or phosphatidic acid), an optimal
degree of unsaturation of the acyl chains, and an appropriate
size [73]. In resting platelets, phosphatidylserine and other
anionic phospholipids are located on the inner aspect of
the membrane bilayer [74]. Following platelet activation
with thrombin, collagen, or shear stress, phosphatidylserine
moves from the inner to the outer leaﬂet of platelet plasma
membrane. This movement is associated with an increase in
the activation of prothrombinfactor II and factor X [75]a n d
with the appearance of high-aﬃnity binding sites for factors
Va and VIIIa.
The importance of the exposure of anionic phospholipid
for hemostasis in vivo is exempliﬁed by Scott syndrome, a
rare bleeding disorder ﬁrst described in 1979 by Weiss et
al. as an isolated deﬁciency of platelet procoagulant activity
[76]. Platelets of patients’ carriers of this syndrome have a
reduced number of binding sites for factor Va and VIIIa
and did not promote prothrombin or factor X activation.
Furthermore, following platelet activation with thrombin
and collagen, they present a marked decrease in the exposure
of anionic phospholipid at the platelet surface as compared
with normal platelets [77]. The clinical features of these
patients illustrate the importance of platelet procoagulant
activity in secondary hemostasis. Externalization of anionic
phospholipidinplateletsisaccompaniedbythegenerationof
phosphatidylserine-rich microvesicles [78], suggesting that
microvesicles and anionic phospholipid exposure are linked
events.
Several ﬁndings suggest that in addition to its role in
normal hemostasis, platelet microvesiculation may contrib-
ute to the prothrombotic tendencies observed in several
diseases. Platelet-derived microvesicles have been detected in
the circulation in patients with disseminated intravascular
coagulation [79], heparin-induced thrombocytopenia [80],
the antiphospholipid antibody syndrome [81], transient
ischemic attacks [82], and thrombotic thrombocytopenic
purpura [83], conditions associated with either arterial,
venous, and/or microvascular thrombosis. These associa-
tions suggest that while they may be necessary for normal
hemostasis, elevated microvesicle concentrations could pre-
dispose to thrombosis. Thus, conditions that increase the
production or decrease the clearance of microvesicles are
expected to increase the incidence of thrombosis.
The microvesicles bind activated platelets in thrombi
through a molecular bridge between P-selectin glycopro-
tein ligand-1 (PSGL-1) on microvesicles and P-selectin on
platelets. These microvesicles selectively enriched in both
tissue factor and PSGL-1 fuse with activated platelets,
transferring tissue factor to the platelet membrane [84].
Failure of this hemostatic mechanism may explain the ability
of agents that block the PSGL-1-P-selectin interaction to
signiﬁcantly inhibit experimental thrombosis [85]. The role
of tissue factor-bearing microvesicles in normal hemostasis
is an active area of investigation.
6. ClinicalAspectsof Thrombosis and
AspirinUse inCardiovascularDisease
Clearly, platelets play a key role in normal hemostasis and
in the pathogenesis of atherothrombotic disease. Because
both pathological and physiological functions of platelets
are due to the same mechanism, it is diﬃcult to separate
the therapeutic beneﬁts from harmful eﬀects. The ultimate
goal of any antithrombotic treatment is to increment the
eﬃcacy and reduce the risks to the patient. For those
reasons, antiplatelet therapy has become a useful means
of preventing acute thromboembolic artery occlusions in
cardiovascular disease. The rationale for this is an enhanced
activity of circulating platelets and an inhibition of the
release of platelet-derived vasoactive mediators, probably
due to endothelial dysfunction. In spite of the progress in
the ﬁeld of platelets function, aspirin is still considered the
leading drug in the ﬁeld. Below, we discuss the basis for the
use of aspirin as the antiplatelet drug of choice for long-
term oral treatment, speciﬁcally for secondary prevention
of myocardial infarction, and also as a suitable basic but
not maximally eﬃcient drug in percutaneous transluminal
coronary angioplasty (PTCA), and platelet activation during
clot lysis.
6.1. Aspirin: Pharmacology of Antiplatelet Activity. The ben-
eﬁts of antiplatelet therapy for the prevention of thrombotic
events in cardiovascular diseases are evident. Statistical stud-
ies have shown that secondary prevention by antiplatelet
agents reduces the risk of nonfatal myocardial infarction6 Thrombosis
(MI) and stroke by 25% to 30%, and the rate of vascular
death by about 15%, resulting in a signiﬁcant reduction in
overallmortality[86].Thesedatademonstratethat(1)blood
platelets, circulating in an activated state, are important
determinants of arterial thrombus formation and vessel
occlusion and (2) these processes can be antagonized by
appropriate antiplatelet therapy. However, it is also clear
that one of the major problems in clinical use will be the
separationoftheantithromboticeﬃcacyofantiplateletagent
from interference with the physiological platelet function in
hemostasis.
Antiplatelet drugs are classiﬁed on the basis of their site
of action, that is, drugs that inhibit (i) platelet adhesion, (ii)
plateletactivation,(iii)plateletaggregation,and(iv)platelet-
mediated links with inﬂammation [87]. Aspirin belongs to
the group of drugs that inhibit platelet activation. As seen
before, platelet activation can be blocked by inhibited the
TXA2 pathway, ADP pathway, thrombin pathway, and phos-
phodiesterase (PDE). Aspirin meets its eﬀects by inhibiting
the TXA2 pathway in a dose-dependent manner.
Low-dose (75–81mg) aspirin inhibits cycloxygenase-1
(COX-1) in such a way that only TXA2 production is inhib-
ited and not of PGI2. Gastrointestinal tract (GIT) bleeding,
drug interactions, and resistance are major drawbacks of
aspirin. To avoid these drug reactions, work is ongoing for
new strategies such as inhibition of thromboxane synthetase
enzyme and blockade of TPRs receptors. TXA2 synthetase
is not much eﬃcacious clinically, because blockade of this
enzyme results in accumulation of endoperoxide precursors
which are themselves platelet TPR agonists [88].
It was Vane, a researcher, that in 1971 discovered the
mechanism of the analgesic, antipyretic, and anti-inﬂam-
matory actions of aspirin [89]. For his experiments, the
supernatant of a broken cell homogenate from guinea
pig lung was incubated with AA and with diﬀerent con-
centrations of aspirin, indomethacin, or sodium salicy-
late. After 30-minute incubation at 37◦C, prostaglandin
(PG)F2α generation was estimated by bioassay on rat colon.
Vane found a dose-dependent inhibition of PGF2α formation
by all three drugs, indomethacin being the most potent
and sodium salicylate the least. Three control drugs, mor-
phine, hydrocortisone, and mepyramine, had no eﬀect on
prostaglandin synthesis. Two other reports in the same issue
of Nature lent support to this ﬁnding and extended it
considerably.Firstly,SmithandWillis[90]wereinvestigating
the eﬀects of aspirin on platelet behavior. They found that
thrombin added to a suspension of platelets in vitro to
which various concentrations of aspirin had been added
also released lower levels of prostaglandins and caused
less aggregation. Secondly,Ferreira and his colleagues [91]
demonstrated that aspirin and indomethacin blocked the
release of prostaglandins from a perfused, isolated dog
spleen subjected to sympathetic nerve stimulation. These
experiments explained why all the aspirin-like, or nons-
teroid anti-inﬂammatory drugs (NSAIDs) as they became
known, shared the same pharmacological actions: anti-in-
ﬂammatory, analgesic, and antipyretic and the same side
eﬀects of damage to the stomach mucosa, toxicity to the
kidney, and inhibition of platelet aggregation. There was
already evidence suggesting that PGE1 was a pyretic agent
in several species [92] and that PGE2 mimicked the inﬂam-
matory response when injected intradermally [93], leading
to speculations that prostaglandins might be responsible, at
least in part, for the genesis of fever and inﬂammation and
that aspirin-like drugs might owe their therapeutic activity
to their ability to prevent prostaglandin biosynthesis.
In 1976, an enzymatically active COX-1 or prostaglandin
endoperoxide synthase (PGES) was isolated [94]. The
enzyme was cloned and its structure elucidated in 1988
[95]. This membrane-bound hemo- and glycoprotein with
a molecular weight of 71kd is a constitutive enzyme found
in greatest amounts in the endoplasmic reticulum of most
mammalian cells [96].
COX converts AA, a ω-6polyunsaturated fatty acid
PUFA, to prostaglandin H2 (PGH2), the precursor of the
series-2 prostanoids. The enzyme contains two active sites: a
heme with peroxidase activity, responsible for the reduction
of PGG2 to PGH2, and a cyclooxygenase site, where AA
is converted into the hydroperoxyendoperoxide PGG2.T h e
reaction proceeds through H atom abstraction from AA by a
tyrosine radical generated by the peroxidase active site. Two
O2 molecules then react with the arachidonicacid radical,
yielding PGG2 [97].
The COX active site is a long hydrophobic channel, and
Picot et al. [98] presented evidence that most of the aspirin-
like drugs such as ﬂurbiprofen inhibit COX by excluding
arachidonate from the upper portion of the channel. Tyro-
sine (Tyr) 385 and serine (Ser) 530 are situated at the apex of
thelongactivesite.AspirininhibitsCOXbyacetylationofthe
hydroxylgroupofSer530,therebyexcludingaccessforAAto
Tyr 385 by steric hindrance [99]. This covalent bond results
in an irreversible inhibition of COX unlike the reversible
inhibitory action of other NSAIDs. Aspirin acetylates COX
in platelets in the presystemic circulation, where there is a
high concentration of aspirin in the portal vein before its
metabolism by the liver. This inhibition of platelet function
occurs with very low doses of aspirin which have no systemic
eﬀects and provides the basis for the use of daily 75mg doses
of aspirin in the prevention of heart attacks and strokes. It is
irreversible and platelets lose their ability to aggregate until
new platelets are formed, which is within 8 to 11 days in
humans [100].
In 1991, a second COX encoded by a diﬀerent gene from
the ﬁrst COX was discovered [101]. COX-2 is an inducible
enzymethatisexpressedinresponsetoinﬂammatorystimuli
released from bacteria such as lipopolysaccharides, cytokines
released from macrophages like interleukin-1, mitogens, and
growth factors. In terms of their molecular biology, COX-
1 and COX-2 are of similar molecular weight, approxi-
mately 70 and 72kd, respectively, and having 65% amino
acid sequence homology and near-identical catalytic sites.
The most signiﬁcant diﬀerence between the isoenzymes,
which allows for selective inhibition, is the substitution of
isoleucine at position 523 in COX-1 with valine in COX-
2. It makes the active site of COX-2 slightly larger than
that of COX-1. The smaller Val523 residue in COX-2 allows
access to a hydrophobic side pocket in the enzyme (which
Ile523sterically hinders). Drug molecules, such as DuP-697Thrombosis 7
and the “coxibs”, which are derived from it, bind to this
alternative site and are considered to be selective inhibitors
of COX-2 [102, 103]. Aspirin still acetylates serine 516 in
COX-2, but due to the larger size of the catalytic channel, AA
is able to “squeeze past” the acetylated structure and form
15- R-hydroxyeicosatetraenoic acid (15-R-HETE) [104]. The
discovery and characterization of COX-2 explained the vari-
ation in the relative potency of the therapeutic actions of the
NSAIDs, compared to their activity in producing side eﬀects.
A new COX-1 variant named COX-3 present in high
concentrations in dog brain was identiﬁed in 2002 [105].
COX-3 is a splice-variant of COX-1 that retains the intron-1
gene sequence at the mRNA level which encodes a 30 amino
acid sequence inserted into the N-terminal hydrophobic
signal peptide of the enzyme protein. The variant enzyme
wasmoresensitivetoinhibitionwithparacetamolthaneither
COX-1 or COX-2, and it was also more sensitive to the
inhibitory action of nonselective NSAIDs including aspirin.
COX-3 enzyme protein has been identiﬁed by Western
blotting in human tissues, and it is thought to be involved
in the hypothermic and analgesic action of paracetamol in
mice, since paracetamol penetrates easily into the central
nervous system [106].
In brief, aspirin irreversibly inhibits COX-1 by acetylat-
ing serine 529, thereby inhibiting the production of TXA2,
a promoter of platelet aggregation, and prostaglandin I2,
a potent inhibitor of platelet aggregation and powerful
vasodilator,inplateletsandvascularendothelialcells,respec-
tively. In the absence of protein synthesis in platelets, TXA2
inhibition persists for the lifetime of the platelet compared
with vascular endothelial cells, which recover COX-1 activity
shortly after exposure to aspirin. For over 50 years, aspirin
has been the basis of antiplatelet therapy, and it remains so
today [107]. Aspirin may also be of beneﬁt in the primary
prevention of cardiovascular events, but the eﬀect is more
modest, and its recommendation is highly debated due to
the fact that ischemic beneﬁt may be oﬀset by bleeding
complications. Although aspirin is a cost-eﬀective therapy,
it is a weak antiplatelet agent [108], and a considerable
numberofpatientscontinuetoexperienceatherothrombotic
complications, especially high-risk patients, such as those
presented with acute coronary syndrome (ACS) or undergo-
ing percutaneous coronary intervention (PCI).
Despite its universal use, the optimal dose of aspirin for
eﬃcacy and safety remains unclear. Previous studies agree
that aspirin at ≥300mg is similar to aspirin 75–100mg/day
for the prevention of major vascular events and that higher
doses increase the risk of bleeding [108].
Recently, the CURRENT-OASIS 7 trial, a randomized
head-to-head comparison of higher-dose (≥300mg/day)
versus low-dose (≤75–100mg/day) aspirin in patients with
ACS demonstrate similar outcomes from eﬃcacy, without a
diﬀerence in the risk of major bleeding complications [109].
On the other hand, one of the limitations for the use
of aspirin is the emergence of resistance. Some of the theo-
rieswhichsurroundthereasonsforaspirinresistanceinclude
potential isoprostane interaction with aspirin treatment
and emerging pharmacogenomic data in which variants
and polymorphisms of essential role players in aspirin
pharmacology change its eﬃcacy. It is important to note
that isoprostanes can be produced at much higher lev-
els in vivo than the classical prostaglandins/thromboxanes
[110]. Furthermore, it is known that the in vivo levels of
isoprostanes can be enhanced by the presence of vascular
disease compounded with traditional aspirin therapy, which
has also been implicated with increasing isoprostane levels
[110, 111]. Hence, the theory on resistance involves the
theorythatincreasedisoprostanelevels,amongotherfactors,
may contribute to aspirin resistance [112], particularly be-
cause isoprostanes have the capacity to activate platelet
TPRs [110]. Thus, by inhibiting COX-1, and blocking TXA2
synthesis, aspirin appears to facilitate increased isoprostane
production, by making more AA/substrate available for their
production, which, in turn, may alter the antithrombotic
eﬀects of aspirin itself, rendering it less eﬀective.
Genetic polymorphisms of platelet receptors also show
impact on drug resistance. Some of the common receptors
that have polymorphisms which can aﬀect platelet reac-
tivity include a PLA1/A2 single-nucleotide polymorphisms
(SNPs) of GPIIb/IIIa (ﬁbrinogen integrin), C807T SNP of
GPIV (collagen integrin), and variants A, B, C, and D
of GPIb (von Willebrand factor integrin) which comprise
diﬀerent repeating portions in the amino acid sequence
which makes up the receptor [113]. These variants and
diﬀerent polymorphisms can contribute to resistance or
reduced eﬃcacy of certain drugs such as aspirin. Speciﬁcally,
it has been shown that the PLA1/A2 polymorphism was
signiﬁcantly associated with aspirin resistance and have
diminishing eﬀect in the presence of cardiovascular disease
[114]. In addition, other polymorphisms and enzymes
are implicated in potential aspirin resistance including,
UDP-glucuronosyltransferaseUGT1A6enzyme,cytochrome
P450 CYP2C9 metabolic enzyme, xenobiotic ACSM2, and
PTGS1/2 which are responsible for COX1/COX2 coding
[115].Itisimportanttomention,however,thatextrinsicfac-
tors are also important in aspirin resistance. Recent studies
have shown that speciﬁc COX1 A-842G, C50T, and GPIIIa
PLA1/A2 genetic polymorphisms are frequently observed in
Caucasiansandwerenotobservedinpatientsfrommainland
China.Datasuchasthiswouldimplythatmanypeopleinthe
general population may have genetic character which makes
them poor aspirin candidates. Importantly, the presence
GPIIb/IIIa PLA1/A2 polymorphism seems to be related to
an attenuated antiplatelet eﬀect during aspirin treatment, if
compared to individuals that do not present such a genetic
polymorphism [116].
7.A spirininP rim aryP r ev e ntio no f
CardiovascularComplications
Although the use of aspirin in secondary prevention against
cardiovascularcomplicationsiswidelyaccepted,thereiscon-
troversy over the daily use of aspirin for primary prevention
of cardiovascular disease (CVD) in persons who have yet
to demonstrate clinical evidence of CVD. Many studies
have been performed in order to overcome this issue, with
diﬀerent conclusions that have not resulted in a common
accepted protocol.8 Thrombosis
The American Heart Association recommends the daily
use of aspirin (71–326mg) indeﬁnitely in all patients with
known CVD for secondary prevention, unless contraindi-
cated [117]. In 2009, the U.S. Preventive Services Task
Force (USPSTF), based on the results presented in diﬀerent
trials, concluded that aspirin is in fact eﬀective for primary
CVD prevention [118], indicating that aspirin for primary
prevention should be recommended when beneﬁts outweigh
risks. The USPSTF found good evidence that aspirin use
decreases myocardial infarctions in men from 45 to 79
years of age with a 10 year CVD risk but without previous
cardiovascular events and in women from 55 to 79 years of
age with a 10-year stroke risk that have not yet experienced
cardiovascular events. Several online calculators are available
to help physicians determine these risks [119]
Recent studies, however, have questioned whether the
beneﬁts of daily aspirin for primary CVD prevention out-
weigh the risks of gastrointestinal (GI) and intracerebral
(IC) hemorrhage [108, 120, 121]. Currently, two large,
international randomized controlled trials (n>10,000) are
investigating the beneﬁt of daily aspirin therapy for primary
CVD prevention in select populations: the ASCEND trial (a
study of cardiovascular events in diabetes) and the ASPREE
trial(aspirininreducingeventsintheelderly),butconclusive
results from these trials should be available within the next
ﬁve years.
Inaddition,arecentmeta-analysisofsixprimarypreven-
tion trials in women found that the cardiovascular beneﬁt of
aspirin is frequently outweighed by the risks of bleeding. In
this study, there was a 12% proportional reduction in serious
vascularevents(0.51%aspirinversus0.57%controlperyear;
P = 0.0001), primarily owing to a reduction in nonfatal
myocardial infarction (MI), but there was not signiﬁcant
reduction in events such stroke or vascular mortality [108].
Those results correlate to those presented in a previous trial
involving 39,876 relatively healthy women of 45 years and
older. This study suggested that daily aspirin therapy may
not decrease in a highly signiﬁcant level the risk of acute
myocardialinfarctioninwomenalthoughtherewasobserved
a 17% decreased risk of stroke [122], showing that the use of
aspirin as primary CVD prevention is dependent not only on
the age but also on the gender of the patient.
Aspirin for primary CVD prevention should be avoided
in persons who have had a GI or cerebral bleeding episode
and in those who are at risk of bleeding problems (e.g.,
bleeding disorder, severe liver disease, thrombocytopenia,
and concomitant anticoagulant therapy). For persons with
an aspirin-induced bleeding ulcer, aspirin use in combina-
tion with a proton pump inhibitor may be safely restarted
after the ulcer has healed [123]. A randomized controlled
trial found that in those taking low-dose aspirin who
had GI bleeding, continuous aspirin therapy may increase
the risk of recurrent GI bleeding but potentially reduces
cardiovascular and cerebrovascular mortality rates [124].
Eradication of Helicobacter pylori decreases the risk of
recurrent GI bleeding in those taking low-dose aspirin [125],
while others studies found that enteric-coated or buﬀered
aspirin did not decrease the risk of GI toxicity [126].
Since the absolute risk of CVD is much lower among
patients being treated for primary prevention, some clini-
cians prefer to be more cautious and reserve aspirin therapy
only for those who will clearly beneﬁt, such as those with
established disease. To help determine the eﬃcacy of aspirin
in primary prevention among patients with risk of CVD,
the results of ASPREE and aspirin to reduce risk of initial
vascular events (ARRIVE) trials are awaited.
At present, the factor most strongly associated with
appropriate aspirin use is a conversation between the patient
andthephysician[127].TheNationalCommitteeforQuality
Assurance has proposed that health plans measure their
members’ use of aspirin, as well as the extent to which physi-
cians discuss aspirin use with their patients. Determining
patients’ CVD risk and discussing appropriate aspirin use
with them should be a priority for all physicians in order to
implementanadequatepreventionofcardiovasculardiseases
for each speciﬁc patient [119].
8. The Futureof Antiplatelet Therapy in
CardiovascularDiseases
Since TXA2 is the primary product of COX-1-dependent
metabolism of AA, whose biological actions are mediated
through the TXA2 receptor (TPR), and because of the
limitation associated with aspirin use, including severe
gastrointestinal toxicity, bleeding complications, potential
individual response, variability, and poor eﬃcacy in some
cardiovascular diseases and procedures, new interest has
been focused towards additional TXA2-associated drug tar-
gets,inparticularTXA2 synthase(TS)andtheTPR.Previous
attempts to develop TPS inhibitors and TPR antagonists
havefailedmainlyduetopoorpharmacodynamicproperties.
Persistent and complete platelet inhibition, as attained with
aspirin, has not been achieved by these compounds. Despite
the lack of clinical success, TS/TPR remains an attractive
target, because other antiplatelet agents and anticoagulants
are associated with comparable or greater risks. In fact, the
American Heart Association (AHA) has recently published
a scientiﬁc update for clinicians, based on new data from
randomized controlled trials of COX-2 selective inhibitors
[128], reinforcing previous warnings regarding drugs like
rofecoxib, which was withdrawn in 2004 due to a high
risk of heart attack and stroke, or celecoxib which in the
Adenoma Prevention with Celecoxib clinical trial was sus-
pended by the National Institutes of Health, because of
increased cardiovascular events within the participants. At
the end of 2004, the FDA issued a public health advisory
summarizing the agency’s recent recommendations for the
use of the NSAID products Vioxx, Bextra, Celebrex, and
Naproxen [129, 130]. The conﬁrmation of the risk of those
drugs together with the complexity to follow up all the rec-
ommendations for the safe use of such medications sup-
ports the superiority of TXA2 or TPR inhibitors in terms of
clinical safety and eﬃcacy, which remain as open questions
that are the focus of current research [131].
In summary, low-dose aspirin is associated with a 25%
reduction of secondary MI and stroke and 30% reduction
on primary MI [86]. Aspirin inhibits COX-1 and at higherThrombosis 9
concentrations COX-2. Secondary eﬀects of platelets inhibi-
tion, including reduced reactive oxygen species ROS, inﬂam-
matory cytokine, growth factor generation, and improved
endothelial function, likely contribute to the overall beneﬁ-
cial eﬀect. However, the reduced risk of arterial thrombosis
cannot be dissociated from an increased risk of bleeding
complications. This is particularly problematic in the upper
gastrointestinal (GI) tract and in the brain. For secondary
prevention, the beneﬁt from aspirin outweighs the risk, but
in low-risk populations, the risk of intracranial bleeds and
serious GI adverse reactions is numerically balanced with the
beneﬁt [132]. However, aspirin is the primary antiplatelet
aggregation drug used at present in combined therapies
aimed to prevent further thrombotic events associated with a
primary disease that presents high risk of embolic processes
that could result in fatal outcomes.
9. Antiplatelet Therapy in
NeurologicalDiseases
Anticoagulant treatment in neurology aims to reduce the
risk of stroke as consequence of acute or chronic cardiac
diseases. Transient ischemic attacks are a good indicator of
the need for prophylactic antiplatelet/anticoagulant therapy.
About 30% of patients with stroke have a history of transient
ischemic attacks and proper treatment of the attacks is an
importantmeansofprevention.Theincidenceofstrokedoes
not relate to either the number or the duration of individual
attacks, but is increased in patients with hypertension or
diabetes. The risk of stroke is highest in the month after a
transient ischemic attack, particularly in the ﬁrst 48 hours,
and progressively decreases thereafter [133].
An important cause of transient cerebral ischemia that
can be prevented by using the appropriate antiplatelet ther-
apy is embolization. In many patients with these attacks, a
source is readily apparent in the heart or a major extracranial
arterytothehead.Cardiaccausesofembolicischemicattacks
include atrial ﬁbrillation, rheumatic heart disease, mitral
valve disease, infective endocarditis, atrial myxoma, and
mural thrombi complicating myocardial infarction. Patients
with high cholesterol levels may present atherosclerotic
changes in the region of the carotid bifurcation extracra-
nially. Also, patients with acquired immunodeﬁciency virus
(AIDs) have an increased risk of developing transient is-
chemic deﬁcits or strokes.
Less common abnormalities of blood vessels may cause
transient ischemic attacks. Furthermore, ﬁbromuscular dys-
plasia, atherosclerosis of the aortic arch, and inﬂammatory
arterial disorders such as giant cell arteritis, systemic lupus
erythematosus, polyarthritis, and granulomatous angiitis are
alsoriskfactorsfortransientischemicdeﬁcitorstrokeaswell
as hematologic hyperviscosity syndromes [133].
Becauseoftheelevatednumberoffactorsthatcaninduce
stroke, to ﬁnd a balance in long-term antiplatelet therapy
is important. Guidelines recommend an early initiation
of antiplatelet/anticoagulant drugs when there is a cardiac
source of embolization. Since comparative studies on the
best starting dose for initiating aspirin therapy to achieve a
rapidantiplateleteﬀectdonotexist[134],approvedprotocol
indicatesinitialtreatmentwithwarfarin.ThetargetisanINR
of 2.0 to 3.0 (laboratorymeasurementof prothrombin time).
If the INR is within the range expected, the CT scan shows
no evidence of hemorrhage, and the cerebrospinal ﬂuid
is clear, antithrombotic treatment may be started without
delay, including aspirin treatment [133].
The anticoagulant approach after an ischemic attack or
a stroke cannot be transferred directly from the antiplatelet
treatment of coronary or peripheral disease to the treat-
ment of patients with acute stroke. This is because of the
heterogenic stroke cases and the bleeding vulnerability of
the brain after acute cerebrovascular ischemia [135]. When
treating acute stroke patients, neurologists try to reduce the
risk of recurrent thromboembolic events but at the same
time fear an excessive risk of cerebral bleeding. Data of
the IST and CAST study groups showed an insigniﬁcant
increase of hemorrhagic stroke with aspirin doses of either
160mg or 300mg and no elevated net hazard in patients
who were inadvertently randomized after a hemorrhagic
stroke [125]. The current guidelines recommendations on
aspirin dosages for acute stroke patients are based on these
two studies. At present, bedside testing of the antiplatelet
eﬀect of aspirin has become available using impedance
aggregometry. In fact, studies evaluating dose-time response
relationship of diﬀerent aspirin dosages in healthy volunteers
have been recently performed [136, 137]. Those studies
have showed that the antiplatelet eﬀect diﬀers signiﬁcantly
depending on aspirin starting dosages (500mg iv, 500mg
po, 200mg/day/2days, and 100mg/day/5days). Also, a high
inter- and intraindividual variability of antiplatelet therapy,
withaloadingdoseafterthestrokeof500mgaspirinIV,used
to ensure an early platelet inhibitory eﬀect in acute stroke
patients. However, there are not enough conclusive clinical
studies to deﬁne the best way and time to initiate antiplatelet
therapy with aspirin.
Lowering the risk levels of clot formation with anti-
platelet/anticoagulant therapy is especially important when
atrialﬁbrillationisthemainfactorthatcaninduceembolism
and stroke. Using pooling data from 5 prevention trials in
atrial ﬁbrillation, the overall annual rate of stroke was 4.5%
in the control group compared with 1.4% in warfarin group
[138], equal to a total reduction of 68% for ischemic stroke
attributable to warfarin [139]. Warfarin eﬃcacy was consis-
tent across all the studies and subgroups of patients, and
balancedagainstminimalchangesintheannualrateofmajor
hemorrhage, which was deﬁned as intracranial bleeding or
bleeding requiring hospitalization or 2 units of blood. This
pooled analysis reported annual rates of major bleeding of
1% in controls and 1.3% in warfarin-treated patients.
In contrast, the eﬃcacy of aspirin for stroke prevention
in AF was less consistent. The Second Copenhagen Atrial
Fibrillation, Aspirin, and Anticoagulant Therapy (AFASAK
2) study showed a nonsigniﬁcant decrease in risk of stroke
with 75mg aspirin, while the Stroke Prevention in Atrial
Fibrillation(SPAF)studyfoundasigniﬁcantdecreaseof44%
associated with 325mg aspirin [136, 137]. The investigators
found identical rates of major bleeding in the control
(1.0%) and the aspirin group (1.0%). A later meta-analysis
of aspirin therapy versus placebo found a 19% reduction in10 Thrombosis
the overall incidence of stroke, with no evidence favoring
one dose of aspirin over another [140]. Since then, many
trials have been performed including patients with persistent
or permanent AF. Anticoagulation was found to reduce all-
cause mortality by 33% and a combined outcome of stroke,
systemic embolism, and death by 48% [141].
Thepersistentdisparitybetweenactualstrokeprevention
practices in chronic ﬁbrillation patients and published stroke
prevention guidelines was recently examined. The results
indicated, unfortunately, that anticoagulation therapy aimed
to prevent stroke after cardiac or other systemic illness that
present high risk of embolism is underused [142]. On the
other hand, based on the encouraging results obtained using
aspirin, new trials using both aspirin and clopidogrel are
being tested at present. Those trails also aim at overcoming
aspirin resistance, a growing complication of aspirin treat-
ment. (e.g., reduce the low response incidence of aspirin
and clopidogrel therapy after coronary stent). To achieve this
aim, 504 patients were included in the study. The antiplatelet
therapy included a loading dose of 600mg clopidogrel and
500mg aspirin, followed by 75mg clopidogrel and 100mg
aspirin once daily. The results for clopidogrel revealed that
in order to overcome low response to clopidogrel, it would
be eﬀective to increase the dose of clopidogrel 150mg daily.
The importance of this study resides in the fact that many
laboratory values like elevated C-reactive protein as well as
acute coronary syndrome, diabetes mellitus, renal failure,
and reduced left ventricular function are risk factors to
determineclopidogrelresistance.Ontheotherhand,patients
with elevated hemoglobin, serum creatinine, and C-reactive
values are directly related to aspirin resistance. So, following
a structured therapy plan based on a “test and treat” strategy
could signiﬁcantly reduce the risk of inadequate antiplatelet
therapy [143].
10. Conclusion
Platelets participate in both hemostasis and thrombosis by
forming aggregates on an injured intimal surface. Thus,
many platelet receptors and enzymes have been targeted
by “antiplatelet” agents, for example, COX-1, which is
targeted by aspirin, for therapeutic purposes. Also, recent
studies indicate that inhibition of COX-1 is associated with
a signiﬁcant decrease in collagen-induced aggregation of
human platelets and to a decreased release of platelet ADP.
Thischaracteristichasmadeaspirinoneofthedrugsusedfor
preventionoffataleventsthatcouldariseasaconsequenceof
thrombotic events. Nevertheless, recent reports have shown
an increased number of patients under treatment with
aspirin that present with resistance. Consequently, the lack
of an eﬀective method of measurement of the levels of
antiaggregant eﬀect induced by the chronic use of aspirin
in the past has been a limitation for its use for prevention
in patients with episodes of transient ischemic disorders
or stroke. New antiplatelet drugs, such as the adenosine
diphosphate receptor inhibitors or GPIIb/IIIa inhibitors
have been developed with the aim to replace aspirin as
antiaggregant agent. However, none of these are expected
to replace the conventional drugs in multiple therapeutic
approaches. ADP receptor inhibitors are used together with
aspirin to overcome possible patient resistance, and new
protocols are being proposed to replace the older protocols
based on trials performed in the last decade. The use of
new techniques for determining the levels of antiaggregation
obtained after aspirin treatment, like platelets impedance
aggregometry, is making possible monitoring the risk of the
patient under preventive treatment for stroke. This gives
therapists the tools for the adequate use (dose and timing) of
aspirin for antiplatelet therapy, by oﬀering more protection
against thrombiembolism with lower bleeding risk and
simpler dosing and monitoring. New protocols based on
those premises are being generated in order to give to the
therapist and the patient the level of conﬁdence necessary for
a better prevention and treatment of thrombotic events.
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